Last updated: April 19, 2026

Application No. 18/177,787

METHODS FOR PROMOTING ANTI-TUMOR IMMUNE RESPONSE IN A SUBJECT IN NEED THEREOF USING ENCAPSULATED INTERLEUKIN 12

Non-Final OA

Filed

Mar 03, 2023

Examiner

BELYAVSKYI, MICHAIL A

Art Unit

1644

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Spectrum Pharmaceuticals Inc.

OA Round

1 (Non-Final)

This examiner grants 64% of cases after interview

— +27.2% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1091 resolved cases, 2023–2026

Examiner Intelligence

BELYAVSKYI, MICHAIL A View full profile →

Grants 64% of resolved cases

Career Allow Rate

697 granted / 1091 resolved

+3.9% vs TC avg

Strong +27% interview lift

Without

With

+27.2%

Interview Lift

resolved cases with interview

Typical timeline

3y 1m

Avg Prosecution

77 currently pending

Career history

1168

Total Applications

across all art units

Statute-Specific Performance

§101

2.3%

-37.7% vs TC avg

§103

29.0%

-11.0% vs TC avg

§102

9.7%

-30.3% vs TC avg

§112

10.9%

-29.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1091 resolved cases

Prosecution Timeline

Mar 03, 2023

Application Filed

Sep 10, 2025

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/000,096

Patent 12599675

NOVEL CONJUGATE OF IMMUNE-STIMULATING IL-2 ANALOG AND PREPARATION METHOD THEREOF

2y 5m to grant Granted Apr 14, 2026

18/903,162

Patent 12589113

PREPARATION OF A THERAPEUTIC COMPOSITION FOR TREATING AUTOIMMUNE DISEASES

2y 5m to grant Granted Mar 31, 2026

17/910,967

Patent 12584125

METHODS AND USE OF CHIMERIC PROTEINS

2y 5m to grant Granted Mar 24, 2026

17/848,590

Patent 12577581

USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS

2y 5m to grant Granted Mar 17, 2026

17/823,454

Patent 12570959

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

2y 5m to grant Granted Mar 10, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

1-2

Expected OA Rounds

64%

Grant Probability

91%

With Interview (+27.2%)

3y 1m

Median Time to Grant

Low

PTA Risk

Based on 1091 resolved cases by this examiner. Grant probability derived from career allow rate.